SLC5A2 and type 2 diabetes mellitus: Overall, the evidence synthesized from these diverse study designs suggests that SGLT2 inhibitors may have a beneficial effect on serum magnesium levels in patients with T2DM and potentially in other conditions associated with hypomagnesemia.